Drug intelligence / Profile preview

vecantoxatug

Development stage: Phase 3
Lead developer: Zhixiang Jintai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

**Vecantoxatug** is a recombinant humanized monoclonal antibody targeting the Clostridium tetani toxin (TeNT), a neurotoxin responsible for tetanus. It specifically binds to TeNT, neutralizing its activity and preventing tetanus symptoms. Developed by Chongqing Genrix Biopharmaceutical Co., Ltd., it is under investigation for infectious diseases, particularly tetanus prophylaxis or treatment in adults.[13][16][19][21]

Targets

TTC (Tetanus neurotoxin heavy chain fragment C)

Beyond the preview

Go deeper on vecantoxatug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vecantoxatug.

Explore the full profile